Clinical Trial Update: CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on CD19-targeted CAR-T cell therapy being tested in relapsed/refractory leukemias and lymphomas (Phase 1 and Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Prolymphocytic Leukemia
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• CD19-targeted CAR-T cell therapy

Snippet

Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Conditions: Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: UNKNOWN